Ginkgo extract analysis reports benefits in a specific dementia subgroup
Pooled trial data suggested improvements in cognition and daily functioning after prior stroke, but the abstract gives no effect sizes or treatment duration.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
A pooled subgroup analysis found statistically significant improvements in cognition, daily activities and overall clinical ratings with a proprietary ginkgo extract compared with placebo. Participants had mild to moderate dementia and a previous cerebral infarction confirmed on brain imaging. The findings need confirmation in trials designed specifically for this patient group.
The abstract reports significance tests without effect sizes, confidence intervals or treatment duration. Because this was a subgroup analysis of existing trials, it leaves uncertainty about the size and relevance of the reported benefits.
Who the evidence concerns
The analysis focused on participants with both dementia and a history of cerebral infarction. It does not establish whether this extract helps people without dementia, people with other stroke histories, or people using different ginkgo products.
What safety reporting showed
Adverse events and reported drug reactions occurred at similar rates in the extract and placebo groups. Without counts or duration in the abstract, that comparison cannot establish long-term safety or rule out uncommon harms.
The original publication
Ginkgo biloba extract EGb 761 in patients with dementia and a history of cerebral infarction-meta-analysis of pooled data from randomised clinical trials.
Feng JX, Zheng MQ, Tian X et al.
Front Neurol · 2025
- PubMed ID
- 41908799
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.